Deferoxamine
1
Reactions 1480, p16 - 30 Nov 2013 S Deferoxamine Acute interstitial pneumonia: case report A 43-year-old man developed acute interstitial pneumonia while receiving deferoxamine. The man, who had myelodysplastic syndrome, started thalidomide and stanozolol. He then started an IV infusion of deferoxamine 25 mg/kg/day for five consecutive days a week. On the 16th day of treatment, he began to develop a hacking cough and coughed up a small amount of rust-coloured sputum. He also developed shortness of breath and a progressive dyspnoea. He had cyanotic lips, coarse rales and fine crackles over his lower lung lobes. The man was considered to have pulmonary infections, and received cefodizime and supplemental oxygen. However, his dyspnoea and lung crackles worsened, and he was coughing more frequently. A chest CT showed diffuse and interstitial infiltration in both lungs with frosted-glass-like shadows and decreased transmittance. His breathing difficulty became severe and his mobility was limited. Bronchoscopy showed a large amount of tissue and a small number of neutrophils in his lung cavity. His alveolar epithelium showed signs of proliferation, fusion, degeneration and shredding. He was diagnosed with acute interstitial pneumonia. Since deferoxamine was considered to be the cause of the interstitial pneumonia, the drug was withdrawn, and he started methylprednisolone. Three days later, his coughing and dyspnoea was significantly alleviated. A follow-up CT scan showed great improvement. Subsequently, methylprednisolone was reduced, and he fully recovered from dyspnoea and coughing. Author comment: This paper reports one case of interstitial lung damage induced by deferoxamine in treating a patient with myelodysplastic syndrome. Wang XJ, et al. Deferoxamine-induced interstitial pulmonary injury: a case report and literature review. Zhonghua Xue Ye Xue Za Zhi 33: 872-3, No. 10, Oct 2012 [Chinese; summarised from a translation] - China 803096206 1 Reactions 30 Nov 2013 No. 1480 0114-9954/13/1480-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
Transcript of Deferoxamine
Reactions 1480, p16 - 30 Nov 2013
SDeferoxamine
Acute interstitial pneumonia: case reportA 43-year-old man developed acute interstitial pneumonia
while receiving deferoxamine.The man, who had myelodysplastic syndrome, started
thalidomide and stanozolol. He then started an IV infusion ofdeferoxamine 25 mg/kg/day for five consecutive days a week.On the 16th day of treatment, he began to develop a hackingcough and coughed up a small amount of rust-colouredsputum. He also developed shortness of breath and aprogressive dyspnoea. He had cyanotic lips, coarse rales andfine crackles over his lower lung lobes.
The man was considered to have pulmonary infections, andreceived cefodizime and supplemental oxygen. However, hisdyspnoea and lung crackles worsened, and he was coughingmore frequently. A chest CT showed diffuse and interstitialinfiltration in both lungs with frosted-glass-like shadows anddecreased transmittance. His breathing difficulty becamesevere and his mobility was limited. Bronchoscopy showed alarge amount of tissue and a small number of neutrophils in hislung cavity. His alveolar epithelium showed signs ofproliferation, fusion, degeneration and shredding. He wasdiagnosed with acute interstitial pneumonia. Sincedeferoxamine was considered to be the cause of the interstitialpneumonia, the drug was withdrawn, and he startedmethylprednisolone. Three days later, his coughing anddyspnoea was significantly alleviated. A follow-up CT scanshowed great improvement. Subsequently,methylprednisolone was reduced, and he fully recovered fromdyspnoea and coughing.
Author comment: This paper reports one case ofinterstitial lung damage induced by deferoxamine in treating apatient with myelodysplastic syndrome.Wang XJ, et al. Deferoxamine-induced interstitial pulmonary injury: a case reportand literature review. Zhonghua Xue Ye Xue Za Zhi 33: 872-3, No. 10, Oct 2012[Chinese; summarised from a translation] - China 803096206
1
Reactions 30 Nov 2013 No. 14800114-9954/13/1480-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
